Nirsevimab vaccine
RSV monoclonal antibody (Beyfortus) · IAP (high-risk)
| When to give | High-risk infants only, entering their first RSV season (up to 24 mo through second season). Not universal. |
|---|---|
| Dose | 50 mg if body weight <5 kg; 100 mg if ≥5 kg. Second RSV season: 200 mg (2 × 100 mg). Single-dose pre-filled syringe (50 mg/0.5 mL or 100 mg/0.5 mL). |
| Route | Intramuscular |
| Site | Anterolateral aspect of thigh |
| Schedule / interval | Single dose per RSV season (long-acting monoclonal antibody, not a vaccine). |
Catch-up schedule
Give before onset of RSV season; a second-season dose (200 mg) for children who remain vulnerable up to 24 months.
Adverse events (AEFI)
Rash (~0.9%), injection-site reactions (~0.3%). Rare hypersensitivity. Efficacy ~75–83% vs medically-attended RSV LRTI.
Brands available in India
Beyfortus (AstraZeneca/Sanofi; marketed in India by Dr Reddy's)
Special considerations
2025 NEW — restricted to HIGH-RISK infants (prematurity <32 wk, BPD, significant CHD, severe immunocompromise, severe neuromuscular disease), after parental counselling. NOT recommended universally. Contraindicated if serious hypersensitivity to nirsevimab. Store 2–8°C (may keep 20–25°C ≤8 h).
Common questions
When is the Nirsevimab vaccine given?
High-risk infants only, entering their first RSV season (up to 24 mo through second season). Not universal.
What is the Nirsevimab vaccine dose and route?
50 mg if body weight <5 kg; 100 mg if ≥5 kg. Second RSV season: 200 mg (2 × 100 mg). Single-dose pre-filled syringe (50 mg/0.5 mL or 100 mg/0.5 mL). Route: Intramuscular. Site: Anterolateral aspect of thigh.
Can the Nirsevimab vaccine be given late?
Give before onset of RSV season; a second-season dose (200 mg) for children who remain vulnerable up to 24 months.
What are the side effects of the Nirsevimab vaccine?
Rash (~0.9%), injection-site reactions (~0.3%). Rare hypersensitivity. Efficacy ~75–83% vs medically-attended RSV LRTI.
Which Nirsevimab vaccine brands are available in India?
Beyfortus (AstraZeneca/Sanofi; marketed in India by Dr Reddy's)
See the full IAP-ACVIP 2025 immunisation schedule →
About this page
Aligned with the IAP-ACVIP Recommended Immunization Schedule 2025 and compiled from standard paediatric references. Verify against the current product insert, the national schedule and your local protocol.
Spotted something wrong? Report an error on this page — corrections from clinicians are welcome and are reviewed before any change is published.
Last reviewed 2026-08-12.